Skip to content
aiqbench takeMachine Learning

aiqbench analysis

CurvFlow-DTA advances drug-target affinity prediction by integrating dynamic discrete Ricci curvature flow into graph neural networks, addressing limitations in adapting to unseen molecular entities. This approach significantly reduces prediction error on standard benchmarks while requiring only SMILES strings and protein sequences without 3D structural data. The method represents a notable step forward in leveraging differential geometry for robust machine learning applications in drug discovery.
Source coveringarXiv
What this isA model's reading of the article and related coverage, written for aiqbench. Not the publisher's words.

CurvFlow-DTA: dual-graph discrete Ricci curvature flow for drug--target affinity prediction

arXiv3 min read

arXiv:2609.22862v1 Announce Type: new Abstract: Graph neural networks are widely used for drug--target affinity (DTA) prediction, and discrete Ricci curvature has recently been used to characterize molecular graph geometry. Existing curvature-aware DTA approaches mainly use static curvature on the drug graph while representing proteins primarily with sequence-derived features. This leaves pair-adaptive use of graph geometry underexplored, which may limit adaptation to unseen entities in cold-start settings relevant to practical screening. We present CurvFlow-DTA, which replaces a single static curvature representation with weighted Forman curvature flow on both molecular and protein residue--residue contact graphs. A label-independent flow trajectory is precomputed for each entity, and a pair-conditioned selector determines the horizons read by a dual-branch Flow-GINE. A frozen ESM-2 supplies residue-level representations and contact scores used to construct the protein graph. Inference requires only SMILES strings and protein sequences, without a bound complex structure. On Davis and KIBA, CurvFlow-DTA improves on the protocol-matched Ricci-GraphDTA baseline in every warm and cold-start setting. Warm-split mean squared error (MSE) decreases by $19.9\%$ on Davis and $18.9\%$ on KIBA. Across the six cold-start comparisons, MSE decreases by $14.3$--$27.4\%$, with higher concordance index (CI) throughout. Within our compiled set of literature baselines, CurvFlow-DTA achieves the lowest MSE on both warm benchmarks and across four out of six cold-start evaluation settings.

Abstract:Graph neural networks are widely used for drug--target affinity (DTA) prediction, and discrete Ricci curvature has recently been used to characterize molecular graph geometry. Existing curvature-aware DTA approaches mainly use static curvature on the drug graph while representing proteins primarily with sequence-derived features. This leaves pair-adaptive use of graph geometry underexplored, which may limit adaptation to unseen entities in cold-start settings relevant to practical screening. We present CurvFlow-DTA, which replaces a single static curvature representation with weighted Forman curvature flow on both molecular and protein residue--residue contact graphs. A label-independent flow trajectory is precomputed for each entity, and a pair-conditioned selector determines the horizons read by a dual-branch Flow-GINE. A frozen ESM-2 supplies residue-level representations and contact scores used to construct the protein graph. Inference requires only SMILES strings and protein sequences, without a bound complex structure. On Davis and KIBA, CurvFlow-DTA improves on the protocol-matched Ricci-GraphDTA baseline in every warm and cold-start setting. Warm-split mean squared error (MSE) decreases by $19.9\%$ on Davis and $18.9\%$ on KIBA. Across the six cold-start comparisons, MSE decreases by $14.3$--$27.4\%$, with higher concordance index (CI) throughout. Within our compiled set of literature baselines, CurvFlow-DTA achieves the lowest MSE on both warm benchmarks and across four out of six cold-start evaluation settings.

Machine Learning (cs.LG); Differential Geometry (math.DG)

I.2.6; J.3; G.2.2

arXiv:2609.22862 [cs.LG]

(or arXiv:2609.22862v1 [cs.LG] for this version)

https://doi.org/10.48550/arXiv.2609.22862 Focus to learn more arXiv-issued DOI via DataCite (pending registration)

arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website.

Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them.

Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.

Full text under the publisher's open licence · 308 words

Related coverage